Neuronetics (STIM) Expected to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Neuronetics to post earnings of ($0.13) per share and revenue of $29.07 million for the quarter.

Neuronetics Stock Up 2.7 %

Neuronetics stock traded up $0.12 during mid-day trading on Friday, hitting $4.58. The company had a trading volume of 557,033 shares, compared to its average volume of 703,897. Neuronetics has a 1 year low of $0.52 and a 1 year high of $5.92. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The stock has a market cap of $301.43 million, a price-to-earnings ratio of -3.72 and a beta of 1.92. The business has a fifty day moving average of $4.25 and a 200 day moving average of $2.72.

Insider Activity

In other news, EVP William Andrew Macan sold 12,175 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $46,630.25. Following the completion of the transaction, the executive vice president now owns 388,647 shares of the company's stock, valued at $1,488,518.01. The trade was a 3.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Stephen Furlong sold 14,836 shares of Neuronetics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $48,662.08. Following the completion of the sale, the chief financial officer now directly owns 482,572 shares of the company's stock, valued at approximately $1,582,836.16. This represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,369 shares of company stock worth $358,929 in the last 90 days. 8.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group boosted their price objective on shares of Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.